RxDoctor Payments DataLook up a doctor →

Adelle Maynard-Watts, DO

Neurology · Terre Haute, INNPI 1881949576

Payments from drug & device makers

$80,571in general payments, 2019–2025

Across 548 payments — averaging $147.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$74K
  • MDD US Operations, LLC$582
  • Novartis$520
  • Supernus Pharmaceuticals, Inc.$520
  • Eisai Inc.$370
  • EMD Serono, Inc.$301
  • plus $4K from 44 others

What the payments were for

  • Speaking & faculty fees$71,51489%
  • Travel & lodging$3570%
  • Food & beverage$8,47911%
  • Education$2210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,571 in reported general payments places this provider in the 85th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$149,377
Medicare patients
527
Services billed
5,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab11$553,679
UbrelvyUbrogepant273$502,133
AubagioTeriflunomide55$499,111
QuliptaAtogepant296$403,082
Gamunex-CImmune Globul G/Gly/Iga Avg 4635$372,406
Nurtec OdtRimegepant Sulfate225$294,898
AptiomEslicarbazepine Acetate103$224,316
Aimovig AutoinjectorErenumab-Aooe187$185,590
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5015$148,169
AustedoDeutetrabenazine13$125,992
BriviactBrivaracetam60$101,393
Emgality PenGalcanezumab-Gnlm89$85,792
GocovriAmantadine Hcl21$78,188
Teriflunomide23$65,409
RytaryCarbidopa/Levodopa29$57,704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$74,319$905,214569 claims
AstraZenecaSoliris$276$553,67911 claims
SanofiAubagio$203$499,11155 claims
Grifols USA, LLCGamunex-C$26$372,40635 claims
PfizerNurtec Odt$94$294,898225 claims
UCB, Inc.Briviact, Neupro$252$127,63581 claims
Teva Pharmaceuticals USA, Inc.Austedo$232$125,99213 claims
MDD US Operations, LLCGocovri$582$78,18821 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$75$64,984102 claims
Otsuka America Pharmaceutical, Inc.Rexulti$113$38,46727 claims
SK Life Science, Inc.Xcopri$256$35,98830 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$520$28,14717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 neurology providers in Indiana.

Other neurology in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →